Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Corporate Update (May 13, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed May 13, 2026
Period End
May 12, 2026
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed May 13, 2026. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. filed this Form 8-K under Item 8.01 (Other Events) to report that on May 12, 2026 it issued a press release announcing the submission of its New Drug Application (NDA) to the FDA for encaleret as a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1).

The press release is attached as Exhibit 99.1 and incorporated by reference. No financial statements are included in this filing. According to the press release, the Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints.

76%a of participants randomized to encaleret achieved both target serum and urine calcium levels at Week 24, compared with 4.4% of the same individuals while on standard of care, and with 19% of participants who remained on standard of care at Week 24 (p<0.0001). The company reports that encaleret restored endogenous parathyroid hormone in 91.1% of participants on encaleret versus 0% on standard of care at Week 24, and that there were no discontinuations in the encaleret arm. BridgeBio states that encaleret may be eligible for priority review and anticipates a U.S. launch in early 2027.

If approved, it could be the first therapy specifically indicated for ADH1. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, begin the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism in Summer 2026, and continues to enroll the CALIBRATE-PEDS study in pediatric ADH1.

Key Highlights

  1. Submitted a New Drug Application to the FDA for encaleret for ADH1, announced May 12, 2026 and disclosed in this 8-K under Item 8.01.
  2. Phase 3 CALIBRATE trial met all pre-specified primary and key secondary efficacy endpoints.
  3. 76% of encaleret-treated participants achieved both target serum and urine calcium at Week 24, versus 4.4% on standard of care (p<0.0001).
  4. Encaleret restored endogenous parathyroid hormone in 91.1% of participants versus 0% on standard of care at Week 24; no discontinuations in the encaleret arm.
  5. Encaleret may be eligible for priority review; U.S. launch anticipated in early 2027.
  6. Planned EMA Marketing Authorization Application submission in the second half of 2026 and start of RECLAIM-HP Phase 3 in chronic hypoparathyroidism in Summer 2026.
  7. Company cites nearly 2,000 individuals diagnosed in the U.S. with autosomal dominant hypocalcemia since October 2023, based on claims data.

Frequently Asked Questions

  1. What did BridgeBio disclose in this 8-K filing?

    The company disclosed under Item 8.01 that on May 12, 2026 it issued a press release announcing the submission of its New Drug Application to the FDA for encaleret for ADH1. The press release is attached as Exhibit 99.1.

  2. What were the main efficacy results from the Phase 3 CALIBRATE trial?

    All pre-specified primary and key secondary efficacy endpoints were met. At Week 24, 76% of participants randomized to encaleret achieved both target serum and urine calcium levels, compared with 19% of participants on standard of care (p<0.0001).

  3. When could encaleret reach the U.S. market?

    BridgeBio anticipates a U.S. launch in early 2027. The company notes encaleret may be eligible for priority review, and approval is not assured.

  4. What are the company's next steps for encaleret?

    BridgeBio plans to submit a Marketing Authorization Application to the European Medicines Agency in the second half of 2026, begin the RECLAIM-HP Phase 3 study in chronic hypoparathyroidism in Summer 2026, and continues enrolling CALIBRATE-PEDS in pediatric ADH1.

  5. What safety information did the company report?

    The press release describes a favorable safety and tolerability profile, with no discontinuations in the encaleret arm and low rates of serious adverse events with frequency similar between treatment arms.